Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment
Status:
Completed
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral
dose in subjects with severe renal impairment and end stage renal disease not on dialysis.